GlobeNewswire Inc.··Spherix Global InsightsRheumatologists Split on Sotyktu's Market Impact Ahead of FDA Decision
BMS's Sotyktu shows promise for psoriatic arthritis among one-third of surveyed rheumatologists, but analysts expect modest market capture ahead of March 2026 FDA decision.
AMGNBMYCELGrJNJPFE+1psoriatic arthritisTYK2 inhibitor